<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278575</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2012-005770-57</org_study_id>
    <nct_id>NCT02278575</nct_id>
  </id_info>
  <brief_title>Atenativ Effect on Uterine Blood Flow and Preeclampsia</brief_title>
  <official_title>Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be an open controlled pilot study of 6 patients with early-onset severe
      preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients
      will be followed up within the study until three days after delivery. Laboratory analyses and
      uterine and umbiliacal blood flow will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an open controlled pilot study of 6 patients with early-onset severe
      preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients
      will be followed up within the study until three days after delivery. In addition to
      conventional therapy, i.v. administration of Atenativ will be given in a dosage aimed to
      raise the plasma level of AT initially to 120% (1.2 kIU/L) The goal is to achieve and
      maintain plasma activity of about 100% during two weeks. The dose of Atenativ is based on the
      actual plasma level of AT measured 2 hours before the dose. During the first two days of
      treatment plasma samples will be drawn for the measurement of AT activity twice a day, once
      before and 12 hours after infusion in order to monitor the dosage. Thereafter and until study
      discontinuation AT will be measured once a day. The treatment will continue for two weeks if
      plasma AT III is below 100% (1.0 kIU/L).Uterine blood flow is measured before, during and
      after the AT infusion. Demographic data, medical history and other background data (age,
      weight, height, gestational week, smoker or not, gravidity, parity, previous hypertension,
      previous medication etc) will be recorded in order to ensure that the inclusion criteria are
      met and to verify patient identity and inclusion status. The week of gestation when the
      patient is included in the study as well as the week of gestation at delivery is recorded.

      The type of delivery (vaginal or caesarean section as well as planned or acute) will also be
      recorded.. General haemostatic parameters are to be analyzed before start of treatment and
      then every day during treatment and thereafter at least twice a week. Special haemostatic
      parameters are Placental growth factor, S-Flt-1, VEGF and Syndecan-1. They will be sampled
      before start of treatment and during treatment once a week. The samples will be collected and
      frozen and not analyzed before the termination of the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    impossible to recruit participants due to organization changes
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow in uterin and umbilical artery</measure>
    <time_frame>up to day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fetal outcome</measure>
    <time_frame>at birth</time_frame>
    <description>CTG, blood flow, Apgar score, birthweight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications</measure>
    <time_frame>during pregnancy and at delivery</time_frame>
    <description>measurements of bleeding before and after placenta delivery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers of endothelial damage</measure>
    <time_frame>up to day 14</time_frame>
    <description>S-Flt-1, VEGF,Syndecan-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Atenativ concentrate</measure>
    <time_frame>treatment during 2 weeks</time_frame>
    <description>amount needed to maintain normal antithrombin levels</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Antithrombin III Deficiency</condition>
  <arm_group>
    <arm_group_label>Consisting of treatment with Atenativ</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenativ</intervention_name>
    <description>intravenous transfusion</description>
    <arm_group_label>Consisting of treatment with Atenativ</arm_group_label>
    <other_name>antithrombin concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant woman in gestational week 23+0 - 29+0

          2. Severe preeclampsia as defined by international criteria (1,2)

               -  Blood pressure &gt;160/110 mmHg (measured twice 30 minutes apart). proteinuria (&gt;5
                  .0 g/L per 24 hours or &gt;3 + labstick in at least two random samples six hours
                  apart) after 20th gestational week.

               -  Blood pressure &gt;140/90 mmHg and proteinuria &gt;5.0 g/24 h.

               -  preeclampsia ( blood pressure &gt; 140/90 and proteinuria &gt;0.3 g/24 h) with IUGR or
                  subjective symptoms as epigastic pain (HELLP), headache, dizziness or visual
                  disturbancies, oligouri &lt; 600 ml/24 h, coagulation disturbancies.

          3. AT level &lt;0.8 kIE/L

        Exclusion Criteria:1. History of congenital AT deficiency 2. Severe preeclampsia with
        demand on acute delivery within 24 hours according to the investigators judgments 3.
        Concomitant administration of anticoagulants and platelet inhibitors within 2 weeks 4.
        Chronic renal disease 5. Diabetes melittus or gestational diabetes 6. Intrauterine fetal
        death 7. Participation in another clinical study 8. Multiple pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Hellgren, MD,PhD,prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>department Obstetrics, Sahlgrenska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Obstetrics, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost. 2007 Jul;13(3):285-91.</citation>
    <PMID>17636190</PMID>
  </results_reference>
  <results_reference>
    <citation>Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, ten Cate JW. Plasma antithrombin III levels in pre-eclampsia. Clin Exp Hypertens B. 1983;2(1):145-62.</citation>
    <PMID>6872275</PMID>
  </results_reference>
  <results_reference>
    <citation>Aghai E, Brunstein J, Quitt M, Abramovici H, Froom P. Antithrombin III levels in preeclampsia. Isr J Med Sci. 1990 Mar;26(3):142-3.</citation>
    <PMID>2329037</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellgren M, Hägnevik K, Robbe H, Björk O, Blombäck M, Eklund J. Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death in late pregnancy. Gynecol Obstet Invest. 1983;16(2):107-18.</citation>
    <PMID>6618278</PMID>
  </results_reference>
  <results_reference>
    <citation>Hellgren M, Javelin L, Hägnevik K, Blombäck M. Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. Thromb Res. 1984 Aug 15;35(4):459-66.</citation>
    <PMID>6484893</PMID>
  </results_reference>
  <results_reference>
    <citation>Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, Sagara Y, Kajiwara Y, Urata M. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. Thromb Haemost. 2000 Oct;84(4):583-90.</citation>
    <PMID>11057854</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, Maki M; BI 51 017 Study Group. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003 Dec;29(6):645-52.</citation>
    <PMID>14719181</PMID>
  </results_reference>
  <results_reference>
    <citation>Paternoster DM, Fantinato S, Manganelli F, Nicolini U, Milani M, Girolami A. Recent progress in the therapeutic management of pre-eclampsia. Expert Opin Pharmacother. 2004 Nov;5(11):2233-9. Review.</citation>
    <PMID>15500369</PMID>
  </results_reference>
  <results_reference>
    <citation>Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y. Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. J Obstet Gynaecol Res. 2008 Feb;34(1):34-9. doi: 10.1111/j.1447-0756.2007.00677.x.</citation>
    <PMID>18226126</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Margareta Hellgren</investigator_full_name>
    <investigator_title>professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>antithrombin, Atenativ, preeclampsia, blood flow.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>extern monitoring by Gothia Forum</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

